



Improving HPV Vaccination Coverage: Current Issues, Future Prospects and Strategies

Guest Editor:

Dr. Irena Ilic

Faculty of Medicine, University of
Belgrade, Belgrade, Serbia

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Globally, cervical cancer ranks as the fourth most common cancer and fourth leading cause of cancer death in women. According to the International Agency for Research on Cancer, Human papillomavirus (HPV) is considered carcinogenic to humans, particularly for cervix uteri.

Countries are reporting a 65–97% reduction in the occurrence of cervical cancer in the population of vaccinated women, but disparities in cervical cancer burden will likely widen with differences in HPV vaccination coverage. According to the latest WHO data, globally in 2022 the HPV vaccination program coverage in females was 21% with the first dose and 15% with the last dose, while in males the coverage was 6% and 5%, respectively, with coverage varying more than 20-fold between WHO regions. In response to this, WHO updated recommendations for the HPV vaccination schedule.

Improving HPV vaccination coverage is essential in reducing the burden of HPV-related cancers and health inequities. The COVID-19 pandemic has significantly disrupted HPV vaccination worldwide. This Special Issue is focused on current issues, future prospects and strategies aimed at improving HPV vaccination coverage.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com